Your browser doesn't support javascript.
Radical cancer treatment is safe during COVID-19: the real-world experience of a large London-based Comprehensive Cancer Centre during the first wave.
Russell, Beth; Moss, Charlotte; Monroy-Iglesias, Maria; Roberts, Graham; Dickinson, Harvey; Haire, Kate; Innes, Kathryn; Mulji-Shah, Bansi; Castell, Fiona; Al-Salihi, Omar; Lei, Mary; Francis, Angela; Dann, Bill; Jogia, Vikash; Hamid, Hisham; Challacombe, Ben; Simo, Ricard; Fraser, Stephanie; Gousis, Charalampos; Sawyer, Elinor; Tsotra, Eirini; Roca, Jose; Khan, Muhammad; Josephs, Debra; Enting, Deborah; Van Hemelrijck, Mieke; Harris, Victoria; Dolly, Saoirse.
  • Russell B; Translational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
  • Moss C; Translational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK. charlotte.moss@kcl.ac.uk.
  • Monroy-Iglesias M; Translational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
  • Roberts G; South East London Cancer Alliance, London, UK.
  • Dickinson H; South East London Cancer Alliance, London, UK.
  • Haire K; South East London Cancer Alliance, London, UK.
  • Innes K; Cancer Informatics and Data, Guy's and St. Thomas NHS Foundation Trust, London, UK.
  • Mulji-Shah B; Cancer Informatics and Data, Guy's and St. Thomas NHS Foundation Trust, London, UK.
  • Castell F; Guy's Cancer, Guy's and St. Thomas NHS Foundation Trust, London, UK.
  • Al-Salihi O; Guy's Cancer, Guy's and St. Thomas NHS Foundation Trust, London, UK.
  • Lei M; Guy's Cancer, Guy's and St. Thomas NHS Foundation Trust, London, UK.
  • Francis A; Guy's Cancer, Guy's and St. Thomas NHS Foundation Trust, London, UK.
  • Dann B; Cancer Informatics and Data, Guy's and St. Thomas NHS Foundation Trust, London, UK.
  • Jogia V; Cancer Informatics and Data, Guy's and St. Thomas NHS Foundation Trust, London, UK.
  • Hamid H; Guy's Cancer, Guy's and St. Thomas NHS Foundation Trust, London, UK.
  • Challacombe B; Guy's Cancer, Guy's and St. Thomas NHS Foundation Trust, London, UK.
  • Simo R; Guy's Cancer, Guy's and St. Thomas NHS Foundation Trust, London, UK.
  • Fraser S; Guy's Cancer, Guy's and St. Thomas NHS Foundation Trust, London, UK.
  • Gousis C; Guy's Cancer, Guy's and St. Thomas NHS Foundation Trust, London, UK.
  • Sawyer E; Guy's Cancer, Guy's and St. Thomas NHS Foundation Trust, London, UK.
  • Tsotra E; Guy's Cancer, Guy's and St. Thomas NHS Foundation Trust, London, UK.
  • Roca J; Guy's Cancer, Guy's and St. Thomas NHS Foundation Trust, London, UK.
  • Khan M; Guy's Cancer, Guy's and St. Thomas NHS Foundation Trust, London, UK.
  • Josephs D; Guy's Cancer, Guy's and St. Thomas NHS Foundation Trust, London, UK.
  • Enting D; Guy's Cancer, Guy's and St. Thomas NHS Foundation Trust, London, UK.
  • Van Hemelrijck M; Translational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
  • Harris V; Guy's Cancer, Guy's and St. Thomas NHS Foundation Trust, London, UK.
  • Dolly S; Guy's Cancer, Guy's and St. Thomas NHS Foundation Trust, London, UK.
Br J Cancer ; 2022 Jul 15.
Article in English | MEDLINE | ID: covidwho-1937426
ABSTRACT

BACKGROUND:

During the COVID pandemic, there was a paucity of data to support clinical decision-making for anticancer treatments. We evaluated the safety of radical treatments which were delivered whilst mitigating the risks of concurrent COVID-19 infection.

METHODS:

Using descriptive statistics, we report on the characteristics and short-term clinical outcomes of patients undergoing radical cancer treatment during the first COVID-19 wave compared to a similar pre-pandemic period.

RESULTS:

Compared to 2019, the number of patients undergoing radical treatment in 2020 reduced by 28% for surgery; 18% for SACT; and 10% for RT. Within SACT, 36% received combination therapy, 35% systemic chemotherapy, 23% targeted treatments, 5% immunotherapy and 2% biological therapy. A similar proportion of RT was delivered in 2019 and 2020 (53% vs. 52%). Oncological outcomes were also similar to pre-COVID-19. The COVID-19 infection rates were low 12 patients were positive pre surgery (1%), 7 post surgery (<1%), 17 SACT patients (2%) and 3 RT patients (<1%). No COVID-19-related deaths were reported.

CONCLUSIONS:

Whilst there were fewer patients receiving radical anticancer treatments, those who did receive treatment were treated in a safe environment. Overall, cancer patients should have the confidence to attend hospitals and be reassured of the safety measures implemented.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Year: 2022 Document Type: Article Affiliation country: S41416-022-01909-0

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Year: 2022 Document Type: Article Affiliation country: S41416-022-01909-0